Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients

Arthritis and Rheumatism

Volumn 63, Issue 11, 2011, Pages 3439-3447

  Marie, I ^a   Hatron, P Y ^b   Dominique, S ^a   Cherin, P ^c   Mouthon, L ^d   Menard, J F ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE DISEASE; ADULT; ARTICLE; DERMATOMYOSITIS; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; FEMALE; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; POLYMYOSITIS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 80155152643     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30513     Document Type: Article

References (48)

1. Callen JP,. Dermatomyositis. Lancet 2000; 355: 53-7. (Pubitemid 30072189)
2. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Courtois H, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001; 28: 2230-7. (Pubitemid 32947868)
3. Marie I, Menard JF, Hachulla E, Cherin P, Benveniste O, Tiev K, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 2010. E-pub ahead of print.
4. Marie I, Menard JF, Hatron PY, Hachulla E, Mouthon L, Tiev K, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken) 2010; 62: 1748-55.
5. Chen IJ, Jan Wu YJ, Lin CW, Fan KW, Luo SF, Ho HH, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009; 28: 639-46.
6. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK,. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 2010; 138: 1464-74.
7. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ, et al, and the Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22: 245-50. (Pubitemid 36986992)
8. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G,. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63: 297-301. (Pubitemid 38250674)
9. Selva-O'Callaghan A, Labrador-Horrillo M, Munoz-Gall X, Martinez-Gomez X, Majo-Masferrer J, Solans-Laque R, et al. Polymyositis/dermatomyositis- associated lung disease: analysis of a series of 81 patients. Lupus 2005; 14: 534-42. (Pubitemid 41161085)
10. Marie I, Hatron PY, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B,. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998; 25: 1336-43. (Pubitemid 28312352)
11. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
12. Bohan A, Peter JB,. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
13. Benveniste O, Drouot L, Jouen F, Charuel JL, Bloch-Queyrat C, Behin A, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63: 1961-71.
14. Quanjer PH,. Clinical respiratory physiology: standardized lung function testing: working party report: standardization of lung function tests. Bull Eur Physiopathol Respir 1983; 19 Suppl 5: 1-95.
15. Akira M, Hara H, Sakatani M,. Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients. Radiology 1999; 210: 333-8. (Pubitemid 29055297)
16. Ikezoe J, Johkoh T, Kohno N, Takeuchi N, Ichikado K, Nakamura H,. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis. J Thorac Imaging 1996; 11: 250-9. (Pubitemid 26364713)
17. Mino M, Noma S, Taguchi Y, Tomii K, Kohri Y, Oida K,. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol 1997; 169: 83-7. (Pubitemid 27289614)
18. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143-8. (Pubitemid 36183002)
19. Schmidt SL, Sundaram B, Flaherty KR,. Diagnosing fibrotic lung disease: when is high-resolution computed tomography sufficient to make a diagnosis of idiopathic pulmonary fibrosis? Respirology 2009; 14: 934-9.
20. Shin KM, Lee KS, Chung MP, Han J, Bae YA, Kim TS, et al. Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study. Radiology 2008; 249: 328-37.
21. Marie I,. Atteinte pulmonaire au cours des polymyosites et des dermatomyosites: la pneumopathie interstitielle. Presse Med 2006; 35: 683-95. (Pubitemid 43907295)
22. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-64.
23. Morganroth PA, Kreider ME, Okawa J, Taylor L, Werth VP,. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol 2010; 146: 729-38.
24. Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182-5. (Pubitemid 33052247)
25. Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 2007; 101: 1761-9. (Pubitemid 46930707)
26. Ideura G, Hanaoka M, Koizumi T, Fujimoto K, Shimojima Y, Ishii W, et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med 2007; 101: 1406-11. (Pubitemid 46832235)
27. Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 2005; 44: 1282-6. (Pubitemid 41487962)
28. Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007; 26: 1647-54.
29. Verschakelen JA,. The role of high-resolution computed tomography in the work-up of interstitial lung disease. Curr Opin Pulm Med 2010; 16: 503-10.
30. Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59: 677-85. (Pubitemid 351679543)
31. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T,. Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49: 1726-33.
32. Porkodi R, Shanmuganandan K, Parthiban M, Madhavan R, Rajendran P,. Clinical spectrum of inflammatory myositis in South Indiaâa ten year study. J Assoc Physicians India 2002; 50: 1255-8.
33. Takizawa H, Shiga J, Moroi Y, Miyachi S, Nishiwaki M, Miyamoto T,. Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 1987; 14: 102-7. (Pubitemid 17054776)
34. Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV,. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990; 141: 727-33. (Pubitemid 20109165)
35. Schnabel A, Reuter M, Biederer J, Richter C, Gross WL,. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003; 32: 273-84. (Pubitemid 36459277)
36. Sugisaki K, Takeda I, Iwadate H, Kanno T, Nishimaki T, Kasukawa R,. Prevention of progression of interstitial lung lesions by early combination therapy with corticosteroids and cyclosporine/cyclophosphamide in two patients with amyopathic dermatomyositis. Fukushima J Med Sci 2002; 48: 103-10.
37. Tanaka F, Origuchi T, Migita K, Tominaga M, Kawakami A, Kawabe Y, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 2000; 39: 428-30. (Pubitemid 30422104)
38. Yoshida T, Koga H, Saitoh F, Sakamoto M, Harada M, Yoshida H, et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 1999; 38: 733-8. (Pubitemid 29436751)
39. Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46: 124-30. (Pubitemid 44932799)
40. Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005; 32: 1719-26. (Pubitemid 41324810)
41. Mok CC, To CH, Szeto ML,. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol 2003; 32: 181-3. (Pubitemid 36819385)
42. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130: 30-6. (Pubitemid 44116838)
43. Morganroth PA, Kreider ME, Werth VP,. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62: 1496-501.
44. Kobayashi I, Yamada M, Takahashi Y, Kawamura N, Okano M, Sakiyama Y, et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 2003; 42: 371-4. (Pubitemid 36305628)
45. Miyake S, Ohtani Y, Sawada M, Inase N, Miyazaki Y, Takano S, et al. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 128-33. (Pubitemid 34685912)
46. Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/ polymyositis: prediction and treatment with cyclosporine. J Rheumatol 1999; 26: 1527-33. (Pubitemid 29317875)
47. Takada K, Nagasaka K, Miyasaka N,. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38: 383-92. (Pubitemid 41358669)
48. Choy EH, Isenberg DA,. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 2002; 41: 7-13. (Pubitemid 34537914)